The Ovarian Cancer Research And Information Amendments Of 2001

Mr. Speaker, I rise today to announce that I am today introducing the Ovarian Cancer and Research Amendments of 2001. I am proud to be joined by 56 original co-sponsors and would like to invite the rest of my colleagues to join me in support of the bill.
Ovarian cancer is the most lethal cancer of the female reproductive system, primarily because it is so difficult to detect in its early stages. While survival rates are quite high if the disease is found before it spread beyond the ovaries, the five-year survival rate drops to 28% for women who are diagnosed and treated in the later stages of the disease. Only 25% of ovarian cancer cases are caught in the earliest stages.
The Ovarian Cancer and Research Amendments of 2001 have three components. First, it authorizes $150 million for ovarian cancer research: one- half to be spent on basic cancer research and one-half on clinical trials and treatment. The bill requires that priority be given to developing a test for the early detection of ovarian cancer; research to identify precursor lesions and to determine the manner in which benign conditions progress to malignant status; and research to determine the relationship between ovarian cancer and endometriosis. Moreover, the bill requires that appropriate counseling be provided to women participating in clinical trials.   Second, the bill provides for a comprehensive education program to provide information to patients and the public on screening procedures, the genetic basis to ovarian cancer, factors that increase the risk of getting ovarian cancer; and any new treatments for ovarian cancer.   Finally, it requires that the National Cancer Advisory Board include at least one individual who is at high risk of developing ovarian cancer.  I hope all my colleagues will join me in supporting this worthy cause and help to give women a fighting chance against ovarian cancer.

What is the price of Imatinib in India

Msia/Kul 2 Post docs & 3 Research Associates in Cancer research

The Cancer Research Initiatives Foundation (CARIF) is the first independent Malaysian fundamental cancer research organization.  We seek an understanding of the genetic basis of cancers in Malaysia through molecular analysis.  The specific projects are described below:

1)  Identification & characterization of genetic changes in oral, nasopharyngeal & liver cancer using whole genome approaches such as SAGE and microarrays
2)  Characterization of sequence variations in the Asian population that are linked to an increased disposition to breast cancer
3)  Novel cancer therapies derived from local flora: Isolation and characterization of novel light-activated compounds from Malaysian plants

CARIF is now offering the abovementioned positions for scientists who are enthusiastic to join our team.

I.  Post doctoral research scientist (2 positions) You will have a PhD in genetics or related field, preferably with post-doctoral experience.  You will be part of project 1 or 2 described above and report to the CEO and the Board of Trustees.

II.  Research Associate (3 positions) You will assist the Project Leader in project 1 or project 2 above.  You will have an MSc in molecular biology, genetics or related biology field.

 

Eating Lots Of Carbs May Raise Breast Cancer Risk, Study Finds

High-carb diets may increase more than just waistlines. New research suggests they might raise the risk of breast cancer. Women in Mexico who ate a lot of carbohydrates were more than twice as likely to get breast cancer than those who ate less starch and sugar, scientists found. The study is hardly the last word on the subject, but it is one of the few to examine how the popular but controversial low-carb diet craze might affect the odds of getting cancer, as opposed to its effects on cholesterol and heart disease. The new findings also don’t mean that it is safe or healthful to eat lots of meat, cheese or fats, as many people who go on low-carb diets do, experts say.
“There are many concerns with eating diets high in animal fat,” said Dr. Walter Willett, chief of nutrition at the Harvard School of Public Health. “If people do want to cut back on carbohydrates, it’s really important to do it in a way that emphasizes healthy fats, like salads with salad dressings.” Willett worked on the study with doctors at Instituto Nacional de Salud Publica in Cuernavaca, Mexico. It was funded by the U.S. Centers for Disease Control and Prevention, the Ministry of Health of Mexico, and the American
Institute for Cancer Research. Results were published Friday in the journal Cancer Epidemiology, Biomarkers & Prevention.
Fats, fiber and specific foods have long been studied for their effects on various types of cancer, but few firm links have emerged. Being overweight is known to raise risk, but the new study took that into account and still found greater risk from high carbohydrate consumption. Scientists think carbs may increase cancer risk by rapidly raising sugar in the blood, which prompts a surge of insulin to be secreted. This causes cells to divide and leads to higher levels of estrogen in the blood, both of which can encourage cancer.
A study earlier this year suggested that high-carb diets modestly raised the risk of colon cancer. Little research has been done on their effect on breast cancer, and results have been mixed. One study last year found greater risk among young women who ate a lot of sweets, especially sodas and desserts. For this study, researchers enrolled 475 women newly diagnosed with breast cancer and a comparison group of 1,391 healthy women in Mexico City who were matched for age, weight, childbirth trends and other factors that affect the odds of getting the disease.
Women filled out a lengthy food questionnaire developed by Willett and widely used in nutrition studies, and were divided into four categories based on how much of their total calories came from carbohydrates. Those in the top category — who got 62 percent or more of their calories from carbs — were 2.22 times more likely to have breast cancer than those in the lowest category, whose carb intake was 52 percent or less of their diet.
“The findings do raise concern about the possible adverse effects of eating lots of carbohydrates,” especially for people who have diabetes, insulin resistance or are overweight, Willett said. “It adds to the information that diet’s important” with respect to cancer risk, said John Milner, the National Cancer Institute’s chief of nutrition. How applicable the results are to American women is debatable. arbohydrates make up half of the typical American diet — less than what most of the women in this study consumed.
“The main carbohydrates these women ate were corn-derived, including tortillas, and soft drinks and bread,” said Dr. Eduardo Lazcano-Ponce, one of the Mexican physicians who did the study. Corn isn’t fortified with folate and other nutrients as are many grains, cereals and other sources of carbohydrates eaten in the United States, and those nutrients might help prevent cancer, noted Sandra Schlicker, executive director of the American Society for Clinical Nutrition.
Breast cancer rates in the United States are among the highest in the world. Nearly 132 cases are diagnosed for every 100,000 women. In Mexico, incidence is rising and is currently estimated at 38 cases per 100,000 women. But Willett cautioned that those rates are not adjusted for age differences and that the U.S. population is considerably older than Mexico’s and therefore more at risk of cancer.
In the study, women who ate a lot of insoluble fiber — found in whole grains, fruits and vegetables — had somewhat less risk of breast cancer. Fiber can modulate the absorption of carbohydrates. “It leads me to believe that healthier carb sources, or at least diets containing fiber, would be less strongly associated with breast cancer,” said Marji McCullough, a senior epidemiologist and nutrition expert at the American Cancer Society.
Experts say more research is needed through a study that, instead of relying on women’s memories about what they ate, asks them to keep food diaries and then follows them for years afterward to see which ones develop cancer. Finding dietary links to breast cancer is important because diet is one of the few risk factors a woman can easily modify.
“This study alone isn’t enough for people to make changes in their diet, but it’s a cautionary sign,” Willett said. The Institute of Medicine recommends that carbohydrates constitute 45 percent to 65 percent of calories, and that no more than 20 percent should come from added sugars, said Schlicker, who served on the panel that drafted the advice. New dietary guidelines are due to be released next year.

REVEALING MY SECRET RESEARCH

It is almost a year since I have come to this ng.  You heard many times how I verify all I hear, read. Not long ago, there was a research done in Europe which said that the most single reason for cancer in human is lack of respect we experience in our lives. Looking at the people whom I knew, looking into my experiences it stroked me as something very probable.

Almost at the same time coincidentally I started to look into Freemasonry. When I started reading this ng there seemed to be lots of disrespect toward ‘cowans’ non masons and others. Not immediately, but after a while I decided on an experiment.  This ng was a perfect environment for it. Will my cancer return or not if I allow myself to feel that disrespect from you?

While my heart went to others I willingly submitted myself. I had times of scare, of pain, the desire to leave sooner but I was convinced there must be more time, at least a year (on average 18 months) of that treatment to see the results. Now at the request and begging from my family and friends I will leave you.  They say it is enough!!! I we all agree with that. I will allow myself to be observed here in Canada for some time before I go to Europe where loving people beg me to come back.

Meanwhile, I have good news.  I bought myself a bright new home and soon will start entirely new life in a new place. I will not read this ng anymore and please do not comment. I know it now that was the most ‘kooky’ idea I have ever had.

 

NEW VERSION OF TEST FOR CANCER-CAUSING AGENTS NEEDS NO ANIMALS

A new version of a popular test for cancer-causing agents is cheaper, more sensitive and, best of all, animal-free, thanks to a U of G researcher. Prof. David Josephy, Chemistry and Biochemistry, has developed a way of testing substances for cancer-causing potential without using animal tissue. Instead, his version of the Ames test involves gene splicing.

“Nobody has figured a way around using animals until now,” says Josephy. “We hope that no more animals will have to die for the sake of the Ames test.” Two decades ago, the Ames test (named after inventor Bruce Ames, a bacterial geneticist from the University of California at Berkeley) was heralded as a breakthrough in cancer research. Ames’s goal was to eliminate the use of animals in tests for cancer-causing or “mutagenic” agents.

In his efforts to put an end to animal use, Ames came up with a way to use animal tissue for his tests, rather than the whole animal. In animals, cancer-causing agents are inactive until they’re chemically changed or “metabolized” by certain enzymes. When they’re changed, they become dangerous because they’re converted into different forms of chemicals.

Ames chose rodent liver extracts for his test because the liver contains more metabolic enzymes than other organs do. In a test tube, he combined liver cells and bacteria. He used bacteria because they’re so small that billions of cells can be affected by the mutagen in one test, making results easier to observe. When a potential cancer-causing agent is introduced into the test tube, it’s metabolized by the enzymes in the liver and causes DNA damage or mutations to the bacterial cells. DNA damage mutates cells, which results in cancer in animals.

The test has enabled researchers to identify carcinogens such as the charring on burnt food and a chemical used to fireproof children’s pyjamas, which was banned after the discovery was made. The Ames test used only a portion of a rodent’s liver. That meant it reduced the use of animals needed to detect suspected mutagens because one liver provided enough material for hundreds of tests. With the Ames test, mutagen-detection laboratories need to use only a few dozen rodent livers each year instead of the thousands of animals that lifetime feeding tests would require.

Now Josephy has taken that a step further. He has completely eliminated the need for animals to be involved. In the last few years, researchers have identified the gene — called P4501A2 — that makes the enzyme needed to metabolize carcinogens so they become mutagenic. Different enzymes metabolize different carcinogens; the enzyme P4501A2 metabolizes one class of compounds called aromatic amines, the carcinogens in charred material.

Josephy spliced the P4501A2 gene into the bacterial cell responsible for producing the metabolizing enzyme that identifies it as a mutagen. By splicing the gene into the bacteria, he’s made it possible for the bacteria to produce the required enzyme, so that no rat liver is needed. As a result, when potential mutagenic chemicals are introduced, the bacteria are a complete mutagen-detecting package  in themselves.

Josephy has installed a clone of the human P4501A2 gene into the bacteria to make the test even more representative of human metabolism. The cloned human genes come from Peter Guengerich, a collaborator at the Vanderbilt University School of Medicine in Nashville. “It means we can do a much more sophisticated mutagen analysis than we could in the past,” says Josephy. “We’re fulfilling Ames’s goal.” This work is sponsored by the National Cancer Institute of Canada and the Natural Sciences and Engineering Research Council.

 

US-CA, An Associate Scientist in Cell Biology, Cancer Research

COMPANY
Well-equipped U.S. research headquarters of international drug discovery company. Attractive campus. Excellent resources. High caliber of science. Company is committed to cutting edge research. Provides cutting-edge tools and support. Highly collaborative environment.

DESCRIPTION
Cell biology associate scientist for a cancer research group heavily focused on breast cancer. Apply 3 to 5 years of relevant experience ideally acquired within an industrial biotech environment.

RESPONSIBILITIES
Within a cell biology department, support cancer research genomics program focused on breast cancer. Apply knowledge in cell biology, cell based assays, cell-cell and cell-matrix signaling mechanisms, and antibody experience. Develop, optimize and perform cell-based assays to evaluate novel-gene therapeutic candidates. Validate novel protein drug targets utilizing strategies such as neutralizing antibodies and anti-sense oligonucleotide-based gene knock-outs. Another validation method used will be transfections of wild-type and dominant negative protein.

LOCATION
San Francisco Bay Area.
QUALIFICATIONS
BS or MS in cell biology with 3 to 5 years of pertinent experience, ideally within an industrial biotech setting. Broad knowledge of cell biology. Cell based assay experience (ex: proliferation, apoptosis, migrations and/or invasion assays). Experience working with cancer cell lines. The ability to manipulate a cell is important. Two crucial areas of technical knowledge are: 1.) Mammalian cell transfection and 2.) Delivering antisense oligonucleotides. Ideally we are seeking experience in the culture and transfection of primary and established human cell lines. Strong interpersonal and problem solving skills also important..

DESIRED (Not Mandatory)
Possible growth factor experience. Extracellular matrix interaction. Familiarity with: DNA expression vectors. Antisense olignucleotides. Immuno-cytochemistry and antibody characterization. Molecular biology techniques: such as cDNA cloning, DNA and RNA isolation. Northern and Western blot analysis.

COMPENSATION
Competitive salary and benefits.

 

Lycopene for Prostate Cancer – Research Summary

BACKGROUND: Harvard researchers reported in a 2002 article in the Journal of the National Cancer Institute that eating tomato products on a regular basis is associated with a reduced risk of prostate cancer. The research included more than 47,000 participants. Researchers then continued to follow the men for several more years to learn more about the specific foods that seem to protect men from prostate cancer. That research was published this year — also in the Journal of the National Cancer Institute. The study reports men who ate tomato sauce at least twice a week were about 20-percent less likely to develop prostate cancer when compared to men who rarely ate it.
CURRENT RESEARCH: Moffitt Cancer Center in Tampa, Florida is conducting a study to look at the mechanism by which lycopene actually stops the promotion of prostate cancer cells. For the study, men with cancer who are having their prostate surgically removed are participating. Generally, the men wait six weeks after diagnosis before they have the surgery. During the six-week period, each participant is given one of three doses of lycopene or a placebo. Researchers will then compare the cancer cells from the pre-surgical biopsy and to those after surgery to compare the cell growth. So far, more than 50 patients have participated. The preliminary results from this study are expected by the summer of 2004.
Advertisement
SUPPLEMENTS VS FOOD? Lycopene supplements are available on the market, but researchers say the supplements may not offer the same level of health protection. Experts point out that so far most studies have looked at intake of foods in the context of a whole diet. Therefore, including lycopene-rich foods is recommended over taking a supplement. LYCOPENE-RICH FOODS: The best way to include lycopene in your diet is to eat more processed tomato products. Research shows the body better absorbs lycopene when tomatoes are processed. While raw tomatoes have some lycopene, it takes more of them to make the processed foods, meaning there is more lycopene in each serving. Below is a list of foods and their lycopene content:
Lycopene Content in Foods (mg/100g)
Tomato Paste 42.2
Spaghetti Sauce 21.9
Chili Sauce 19.5
Tomato Ketchup 15.9
Tomato Juice 9.5
Pink Grapefruit 4.0
Raw Tomato 3.0

You can visit knolhub to know more about the Dyson DC08 Vacuum cleaner.

Armstrong Promotes Cancer Research

Associated Press

AUSTIN, Texas – With Lance Armstrong pushing for a record sixth consecutive Tour de France title this summer, his cancer research foundation is using the signature color of the world’s most grueling bicycle race for a new fund-raising campaign. The Lance Armstrong Foundation and Nike are promoting the sale of yellow wristbands engraved with the message, “Live Strong.”

“Yellow has taught me the true meaning of sacrifice. Yellow makes me suffer. Yellow is the reason I’m here,” Armstrong said. “Young people with cancer should be empowered to fight hard, dream big and live strong.”

The company will donate $1 million to the foundation, which hopes to raise an additional $5 million through wristband sales. Proceeds will go to the foundation for programs for young people with cancer. Foundation President Mitch Stoller said officials hope the wristbands will become as recognizable as the pink ribbons associated with breast cancer.

Armstrong overcame advanced testicular cancer that had spread to his lungs and brain. He went from having a 50 percent chance to live in 1996 to a string a five straight tour wins from 1999-2003, forever linking himself with the yellow jersey worn by the tour leader and champion.

 

2000CRE1167C BREAST CANCER RESEARCH STAMP REAUTHORIZATION ACT OF 2000

Mr. LAZIO. Mr. Speaker, I rise to introduce the bill entitled the Breast Cancer Research Stamps Reauthorization Act of 2000.
Breast cancer is the most commonly diagnosed cancer among women in the United States. More than 2 million American women are currently living with the disease, 1 million of whom have yet to be diagnosed. This year alone, 182,800 women will be diagnosed with breast cancer. Over 40,000 of them will lose their battle with this killer.
Breast cancer has taken an awful toll on the people of my home state. New York has the second-highest breast cancer mortality rate in the country. Between 1980 and 1994, the incidence of breast cancer in New York increased nearly 18 percent. Enactment of this bill will go a long way toward helping our effort to increase funding for breast cancer research. Only through the help of continued cancer research have more and more people become cancer survivors in recent years.
Since the issuance of the Breast Cancer Research stamp in the summer of 1998, 164 million Breast Cancer Research stamps have been sold rising over $12 million for breast cancer research. The stamp provides a convenient avenue for participation in the battle against this horrible disease. Unfortunately, without congressional intervention, the stamp will expire on July 28, 2000. Valuable research funds, as well as a mechanism to heighten public awareness of this horrible disease, will be lost.
This bill, The Breast Cancer Research Stamp Reauthorization Act of 2000 would extend the sale of the Breast Cancer Research stamp for an additional two years. The stamp would continue to cost 40 cents and sell as a first class stamp. The additional funds that are raised will go directly to breast cancer research at the National Institutes of Health and the Department of Defense.
I am pleased to report that this reauthorization bill has tremendous support throughout the health community. Supporters of the Breast Cancer Stamp Reauthorization Act of 2000 include the American Cancer Society, the American Medical Association, the Y-Me National Breast Cancer Organization, Leadership America, the National Association of Women’s Health, the American Cancer League, the American College of Surgeons, Friends of Cancer Research, and many others.
A Breast Cancer Research Stamp remains just as necessary today as it was when this authority was signed into law two years ago. According to the American Association for Cancer Research, 8 million people are alive today as a result of cancer research. To say that every dollar we continue to raise will save lives, can only underscore the importance of this legislation.
I urge my colleagues to join me in enacting this important legislation.

 

Vitamin D Receptor Polymorphisms and Cancer Risk

PHILADELPHIA Subtle differences in the receptor for vitamin D reverse the anti-cancer action of the sunshine vitamin, increasing the risk of breast cancer in Caucasian women and prostate cancer in African-American men, according to two new studies. The results, in journals published by the American Association for Cancer Research, underscore how naturally-occurring variants of the same gene, called polymorphisms, can have implications for cancer initiation and progression.

For example, in the breast cancer study, British scientists at St. George¹s Hospital Medical School in London found that Caucasian women, who carried specific versions of the vitamin D receptor gene, or VDR, not only experienced increased risk for this cancer but may also be more prone to developing metastases.

Differences in the gene sequence for the vitamin D receptor are associated with breast cancer risk and may also be linked to disease progression said Kay Colston, Ph.D., the senior author of the study, published in the August 15 issue of the journal Clinical Cancer Research. Colston is a Reader in the Department of Cellular and Molecular Medicine at St. George¹s Hospital Medical School.

Among three known variable regions of the VDR gene considered by the research team, the bb and LL variants increased breast cancer risk by almost twofold. The F variant of the gene had no significant effect on breast cancer risk by itself, however when coupled with the LL genotype the risk of breast cancer was increased by a higher factor than the bb or LL genotypes alone. In addition, there was a higher proportion of women with this Œat risk genotype in a sub-group of patients who developed metastatic disease.

A second study, conducted independently, linked a similar change in the vitamin D receptor (VDR) with amplified risk of prostate cancer for African American men. That study appeared in the August issue of Cancer Epidemiology, Biomarkers & Prevention, a sister publication to Clinical Cancer Research.

Intriguingly, the F variant that increases the chance of developing breast cancer when associated with other VDR variants also contributes to increased risk and aggressiveness of prostate cancer in African-American men, according to the Cancer Epidemiology, Biomarkers & Prevention article. This study reported that men with two copies of the F variant almost doubled the risk for prostate cancer developing in African-Americans, but not Caucasians. Furthermore, the same men had twice the risk for developing high grade advanced prostate cancer, according to the research.

More African-American prostate cancer patients carried the homozygous FF variant of the vitamin D receptor than African American men who did not have prostate cancer, said Alice S. Whittemore, Ph.D., the senior author of the paper. Whittemore, who conducts cancer research in the department of Health Research and Policy, the Stanford University School of Medicine, led a multi-institutional team of cancer scientists from Stanford University, the University of Southern California, the University of Hawaii, the British Columbia Cancer Agency and the Northern California Cancer Center.

Neither the b nor L gene variants that altered risk in Caucasian women in the British study contributed to elevated risk for prostate cancer among men. Funding for the prostate cancer studies came from NIH grant CA67044. The UK breast cancer study was funded by Breast Cancer Campaign and the World Cancer Research Fund.